Osteosarcoma cell line growth inhibition by zoledronate-stimulated effector cells.
about
Addition of pamidronate to chemotherapy for the treatment of osteosarcomaAdoptive cell therapy for sarcomaT-Cell-Based Immunotherapy for Osteosarcoma: Challenges and OpportunitiesPrenylated Polyphenols from Clusiaceae and Calophyllaceae with Immunomodulatory Activity on Endothelial CellsAdjuvant bisphosphonates in endocrine-responsive breast cancer: what is their place in therapy?Increased prevalence of bisphosphonate-related osteonecrosis of the jaw with vitamin D deficiency in rats.The Current and Future Therapies for Human Osteosarcoma.Current concepts on the surgical and medical management of osteosarcoma.Reduced-intensity conditioning in allogeneic stem cell transplantation for hematological malignancies: a historical perspective.Potential of human γδ T cells for immunotherapy of osteosarcoma.Adoptive immunotherapy against sarcomas.Adoptive transfer of ex vivo expanded Vγ9Vδ2 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer.Drugs in early clinical development for the treatment of osteosarcoma.Well-differentiated hand liposarcoma with bone metastases treated successfully with zoledronic Acid.Sensitization of human osteosarcoma cells to Vγ9Vδ2 T-cell-mediated cytotoxicity by zoledronate.Valproic Acid Combined with Zoledronate Enhance γδ T Cell-Mediated Cytotoxicity against Osteosarcoma Cells via the Accumulation of Mevalonate Pathway Intermediates.Zoledronic acid inhibits NFAT and IL-2 signaling pathways in regulatory T cells and diminishes their suppressive function in patients with metastatic cancer.Decitabine Enhances Vγ9Vδ2 T Cell-Mediated Cytotoxic Effects on Osteosarcoma Cells via the NKG2DL-NKG2D Axis.
P2860
Q24594269-D220A3E9-77BD-482A-93D7-AA09CDB6D0E9Q27009541-0964583E-F21D-4E7D-AC77-7BCF9172ABAFQ28074619-46B267DD-3B25-40A9-88B4-0A6DF4ADAAC7Q28554642-351A5202-42F6-4C3D-B315-12EA8D388986Q35076216-8EBDED10-AAAE-41CD-93A2-2B2EDFE04059Q35155516-DE7AAD46-3ACB-4F48-AD7E-F68ADD3220B6Q36514299-D62ACCD7-DB21-4E1B-9EDA-9D3B1ED3E672Q37242673-07633B90-4C50-4018-B458-0E2695A0AF07Q37966693-1AA39058-13A3-4431-9047-B47C5D06C04AQ38052064-E9F61324-EB44-4C80-8311-64CCCDEB16A9Q38291193-72B26A8A-4139-48A4-A4D7-A4FAAFC6DE8DQ38730126-F8BD4CEF-CD50-46A4-AB2D-630FA8AC72B2Q38955517-5177FD5B-1EA0-48F7-9B57-1E73AF051B55Q39254815-7962FC34-BAA9-45A5-B081-933BC89F9BAAQ39453295-D289C7AD-107A-4C36-84EE-73E136F825B6Q52657143-33EA15D7-8104-4DB4-BDD4-37E913B8CC45Q52755645-87EFECF2-3775-4966-A3B9-5C534CEE1C1CQ55279130-9E29C516-74C1-43D4-A727-7054A77F9F50
P2860
Osteosarcoma cell line growth inhibition by zoledronate-stimulated effector cells.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Osteosarcoma cell line growth inhibition by zoledronate-stimulated effector cells.
@en
type
label
Osteosarcoma cell line growth inhibition by zoledronate-stimulated effector cells.
@en
prefLabel
Osteosarcoma cell line growth inhibition by zoledronate-stimulated effector cells.
@en
P2093
P1433
P1476
Osteosarcoma cell line growth inhibition by zoledronate-stimulated effector cells
@en
P2093
P356
10.1016/J.CELLIMM.2007.11.005
P577
2007-10-01T00:00:00Z